JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M110345200 on April 29, 2002

J. Biol. Chem., Vol. 277, Issue 28, 25568-25575, July 12, 2002
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/28/25568    most recent
M110345200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greene, B. T.
Right arrow Articles by Torti, S. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greene, B. T.
Right arrow Articles by Torti, S. V.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Activation of Caspase Pathways during Iron Chelator-mediated Apoptosis*

Bryan T. GreeneDagger §, Jackie ThorburnDagger §, Mark C. Willingham§, Andrew ThorburnDagger §, Roy P. Planalp||, Martin W. Brechbiel**, Jamie Jennings-Gee§Dagger Dagger , John Wilkinson IVDagger §, Frank M. TortiDagger §, and Suzy V. Torti§Dagger Dagger §§

From the Departments of Dagger  Cancer Biology,  Pathology, and Dagger Dagger  Biochemistry and the § Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, the || Department of Chemistry, University of New Hampshire, Durham, New Hampshire 03824, and the ** Radiation Oncology Branch, National Institutes of Health, Bethesda, Maryland 20892

Iron chelators have traditionally been used in the treatment of iron overload. Recently, chelators have also been explored for their ability to limit oxidant damage in cardiovascular, neurologic, and inflammatory disease as well as to serve as anti-cancer agents. To determine the mechanism of cell death induced by iron chelators, we assessed the time course and pathways of caspase activation during apoptosis induced by iron chelators. We report that the chelator tachpyridine sequentially activates caspases 9, 3, and 8. These caspases were also activated by the structurally unrelated chelators dipyridyl and desferrioxamine. The critical role of caspase activation in cell death was supported by microinjection experiments demonstrating that p35, a broad spectrum caspase inhibitor, protected HeLa cells from chelator-induced cell death. Apoptosis mediated by tachpyridine was not prevented by blocking the CD95 death receptor pathway with a Fas-associated death domain protein (FADD) dominant-negative mutant. In contrast, chelator-mediated cell death was blocked in cells microinjected with Bcl-XL and completely inhibited in cells microinjected with a dominant-negative caspase 9 expression vector. Caspase activation was not observed in cells treated with N-methyl tachpyridine, an N-alkylated derivative of tachpyridine which lacks an ability to react with iron. These results suggest that activation of a mitochondrial caspase pathway is an important mechanism by which iron chelators induce cell death.


* This work was supported by Grant DK 57781 (to S. V. T.) from the National Institutes of Health. Preclinical development of tachpyridine was supported by a grant from the NCI Rapid Access to Intervention Development Program, National Institutes of Health (to S. V. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§§ To whom correspondence should be addressed: Dept. of Biochemistry, Wake Forest University School of Medicine, Hanes Bldg., Rm. 4057, Medical Center Blvd., Winston-Salem, NC 27157. Tel.: 336-716-9357; Fax: 336-716-0255; E-mail: storti@wfubmc.edu.


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
D. Fu and D. R. Richardson
Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion
Blood, July 15, 2007; 110(2): 752 - 761.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Yu, J. Wong, D. B. Lovejoy, D. S. Kalinowski, and D. R. Richardson
Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond
Clin. Cancer Res., December 1, 2006; 12(23): 6876 - 6883.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. P. Ng, G. Helguera, T. R. Daniels, S. Z. Lomas, J. A. Rodriguez, G. Schiller, B. Bonavida, S. L. Morrison, and M. L. Penichet
Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor
Blood, October 15, 2006; 108(8): 2745 - 2754.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Nie, G. Chen, A. D. Sheftel, K. Pantopoulos, and P. Ponka
In vivo tumor growth is inhibited by cytosolic iron deprivation caused by the expression of mitochondrial ferritin
Blood, October 1, 2006; 108(7): 2428 - 2434.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
S. W. Ryter, J. Alam, and A. M. K. Choi
Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications
Physiol Rev, April 1, 2006; 86(2): 583 - 650.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Turner, C. Koumenis, T. E. Kute, R. P. Planalp, M. W. Brechbiel, D. Beardsley, B. Cody, K. D. Brown, F. M. Torti, and S. V. Torti
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation
Blood, November 1, 2005; 106(9): 3191 - 3199.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. Xie, N. Zhang, H. Zhou, J. Li, Q. Li, T. Zarubin, S.-C. Lin, and J. Han
Distinct Roles of Basal Steady-State and Induced H-Ferritin in Tumor Necrosis Factor-Induced Death in L929 Cells
Mol. Cell. Biol., August 1, 2005; 25(15): 6673 - 6681.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Yuan, D. B. Lovejoy, and D. R. Richardson
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment
Blood, September 1, 2004; 104(5): 1450 - 1458.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Cozzi, B. Corsi, S. Levi, P. Santambrogio, G. Biasiotto, and P. Arosio
Analysis of the biologic functions of H- and L-ferritins in HeLa cells by transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin
Blood, March 15, 2004; 103(6): 2377 - 2383.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Heon, M. Bernier, N. Servant, S. Dostanic, C. Wang, G. M. Kirby, L. Alpert, and L. E. Chalifour
Dexrazoxane does not protect against doxorubicin-induced damage in young rats
Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H499 - H506.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.